Erdafitinib Overcomes FGFR3-TACC3–Mediated Resistance to Osimertinib
Eric B. Haura, J. Kevin Hicks, Theresa A. Boyle
Topics & Concepts
OsimertinibMedicineCancer researchFibroblast growth factor receptorLung cancerCancerTyrosine kinaseCarcinogenesisOncologyFibroblast growth factorEpidermal growth factor receptorInternal medicineReceptorErlotinibLung Cancer Treatments and MutationsFibroblast Growth Factor ResearchPI3K/AKT/mTOR signaling in cancer